Phase 2 N=140 Repurposing Anti-TNF for Treating Dupuytren's Disease
Dupuytren's Disease
Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=35 Collagenase in the Treatment of Dupuytrens Disease
Dupuytren's Disease
Primary: Primary Outcome Measure is Reduction of Flexion Contracture of the Primary Joint. — 91.3; 0 % Joints
Phase 3 N=66 Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
Advanced Dupuytren's Disease
Primary: Reduction in Primary Joint Contracture to 5° or Less — 44.4; 4.8 Percentage of Joints — p=<.001
Phase 3 N=308 AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture
Dupuytren's Contracture
Primary: Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection — 64; 6.8 Percentage of Joints — p=<0.001
Phase 3 N=201 Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
Advanced Dupuytren's Disease
Primary: Reduction in Contracture to 5° or Less — 52.7 percentage of joints
Phase 3 N=715 Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures
Dupuytren's Contracture
Primary: Percent Change From Baseline in Total Fixed Flexion — 74.41 percentage of contracture change
Phase 3 N=286 AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
Advanced Dupuytren's Disease
Primary: Reduction in Contracture to 5° or Less — 41.9 Percentage of joints
Phase 3 N=60 Administration of Two Injections for Multiple Dupuytren's Contractures
Dupuytren's Contracture
Primary: Percent Change From Baseline in Total Fixed Flexion — 75.5 percentage of contracture change
Phase 4 N=5 MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex
Dupuytren's Disease
Primary: The Measured Change in Volume of the Cord by MRI Before and After XIAFLEX Injection and Manual Manipulation. — 482 mm^3 — p=<0.0013
Phase 3 N=6 Collagenase Option for Reduction of Dupuytren's Contracture in Japan
Dupuytren's Contracture
Primary: The Percentage of Participants That Were Successfully Treated With a "Successful Reduction in Contracture to 5°or Less" — 86 % Participants
Phase 3 N=254 Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)
Dupuytren's Contracture
Primary: Total Passive Extension Deficit (TPED) at Baseline for First Injection — 55.0 degrees
Phase 3 N=22 Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's
Dupuytren's Disease
Primary: Health-related Quality of Life (HRQL) Using the Michigan Hand Outcomes Questionnaire (MHQ) — 78.1; 68.3 units on a scale — p=0.05
Phase 2 N=76 Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules
Dupuytren's Disease
Primary: Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements — -81.61; -80.11; -58.30; -41.76 percentage of change…
Phase 4 N=52 Retreatment of Recurrent Dupuytren's Contractures
Dupuytren's Disease
Primary: Clinical Success — 64.5; 45.0 percentage of particpants
Phase 4 N=7 Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb
Dupuytren's Contracture
Primary: Number Patients Obtaining Clinical Improvement (>50% Reduction in Contracture) — 5; 1 participants
Phase 1 N=16 A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture
Dupuytren's Contracture
Primary: Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500 — 0 participants
N/A N=9 Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap
Painful Digital Neuroma
Primary: Static 2-point Discrimination Test — 7.3 mm
N/A N=60 Evaluation of High-Purity Type I Collagen Biologic Wrap to Improve Function After Extensor Tendon Repair of the Hand
Injury of Extensor Tendon of Hand · Tendon Adhesions
Primary: Total Active Motion (TAM) of Involved Finger(s) — 232.4; 201.3 degrees
N/A N=31 LRTI vs Internal Brace for CMC OA
Thumb Carpometacarpal Osteoarthritis
Primary: Postoperative Follow-Up Retention Rate — 17; 13; 0; 2 thumbs
Early Phase 1 N=20 Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients
Systemic Sclerosis
Primary: Raynaud's Condition Scale — 5; 5; 6.5; 3 score on a scale — p=0.256
N/A N=17 Dorsal Wrist Ganglia; Aspiration Alone vs Aspiration and Injection of Platelet Rich Plasma
Ganglion of Wrist
Primary: Number of Participants With a Recurrence of Ganglia — 8; 5 Participants
N/A N=27 Hands on - a Hand Care Guide in Systemic Sclerosis
Scleroderma
Primary: Cochin Hand Functional Scale — 19.24 units on a scale
N/A N=29 4DCT Imaging for Improved Diagnosis and Treatment of Wrist Ligament Injuries
Scapholunate Interosseous Ligament Injury
Primary: Equivalency of 4DCT-based Treatment Plan to Arthroscopic-based Treatment Plan. — 5; 14; 11 Participants
N/A N=26 Endoscopic Trigger Finger Release
Trigger Finger
Primary: Scar Comparison Between Treatment Arms, as Measured by the Patient and Observer Scar Assessment Scale (POSAS) — 27.2; 45.0; 31.2; 44.8 score on a scale — p=0.013
Phase 2 N=12 H-22411: BOTOX® for Peyronie's Disease
Peyronie's Disease
Primary: Average Percent Change of Penile Curvature in Degrees — -21.73; 2.429 percent change — p=0.5154
Phase 3 N=417 Study of AA4500 in the Treatment of Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -37.6; -21.3 percentage of curvature change — p=0.0005
Phase 2 N=14 A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma
Lipoma
Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline
N/A N=183 Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Phase 3 N=415 Study of AA4500 in the Treatment of Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -30.5; -15.2 percentage of curvature change — p=.0059
N/A N=120 Comparison of Two Techniques for the Treatment of Carpal Tunnel Syndrome
Carpal Tunnel Syndrome
Primary: Incidence of Pillar Pain — 14; 24 Participants